Eight-gene signature associated with survival in patients with Diffuse Large B-cell lymphoma
Photo by engin akyurt / Unsplash
Key Takeaway
Note the association between an eight-gene signature and survival in patients with Diffuse Large B-cell lymphoma.
This cohort study investigated the prognostic utility of a novel predictive signature in patients with Diffuse Large B-cell lymphoma (DLBCL). The research focused on a signature characterized by the reactivation of eight genes that are normally silent in tissue-dependent contexts.
The study identified that this eight-gene signature is associated with survival in the studied population. While the specific absolute numbers, effect sizes, and p-values were not reported, the researchers established an association between the gene expression pattern and survival outcomes.
No data were reported regarding the safety, tolerability, or adverse events related to the signature itself, as the study focused on a molecular predictive tool rather than a therapeutic intervention. The study design is observational, identifying an association rather than establishing causality.
Clinically, this signature could potentially be integrated with existing molecular classifications and current prognostic indices to improve patient stratification. Such integration may assist in guiding treatment selection for patients with DLBCL, provided the signature's predictive value is confirmed in larger, prospective cohorts.
More on Diffuse Large B-Cell Lymphoma
High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP.
New Protein Test Predicts Lymphoma Relapse Risk
This retrospective cohort study evaluated 91 patients with de novo diffuse large B-cell lymphoma treated with R-CHOP. High FGR protein expre…
A new protein test identifies diffuse large B-cell lymphoma patients at high risk of relapse before treatment fails, giving doctors a crucia…
High-dose pegylated liposomal doxorubicin shows comparable survival to conventional doxorubicin in DLBCL with reduced toxicity
A Gentler Chemo Version Holds Its Own in Lymphoma
A retrospective cohort of 512 DLBCL patients found comparable 2-year PFS (74.3% vs. 69.6%) and OS (81.4% vs. 83.8%) between overall PLD and …
A gentler chemo drug wrapped in fat bubbles matched standard treatment for lymphoma survival while sharply cutting serious side effects like…
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
Doctors describe treatment response in rare case of dual-lesion lymphoma
A case report and systematic review describes a 65-year-old female with rare dual-lesion DLBCL featuring both GCB and ABC subtypes. After in…
Doctors treated a woman with two different rare lymphoma types in her brain and muscle, achieving stability after adjusting her chemotherapy…
View Original Abstract ↓
Diffuse Large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in the Western world. First-line immunochemotherapy fails in approximately 30-40% of patients, with refractory and relapse patients presenting a dismal prognosis. Currently, these high-risk patients cannot be accurately identified at diagnosis. Using statistical modeling and machine learning approaches applied to large public DLBCL datasets, we identified a novel predictive signature based on the reactivation of eight normally silent tissue-dependent genes associated with survival. We then developed a multiplex RT-MLPseq based assay, compatible with formalin-fixed paraffin-embedded (FFPE) samples and transferable into routine clinical practice, enabling analysis of expression of these eight genes and validated their prognosis impact in an independent real-life cohort. This signature could be integrated with current prognostic indices and molecular classifications to improve patient stratification and guide treatment selection toward a personalized theragnostic approach, thereby enhancing management of non-responder patients.
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients.
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma.
Subcutaneous Mosunetuzumab Shows Promise for Follicular Lymphoma Patients
This Phase 2 primary analysis evaluated fixed-duration subcutaneous mosunetuzumab versus mosunetuzumab IV in patients with relapsed or refra…
A Phase 2 trial found subcutaneous mosunetuzumab had lower rates of severe side effects than the IV version for treating follicular lymphoma…
Meta-analysis links perinatal factors to childhood acute leukemia risk
Perinatal factors linked to higher leukemia risk in children
This systematic review and meta-analysis of 85 studies examined perinatal factors and childhood acute leukemia risk. High birth weight, mate…
A large analysis of 85 studies finds links between birth weight, maternal history, and cesarean sections with childhood leukemia risk.
Meta-analysis links maternal infection in pregnancy to childhood ALL risk
Maternal Infections During Pregnancy Linked to Higher Risk of Childhood Leukemia
This systematic review and meta-analysis of 26 studies found a modest association between maternal infection during pregnancy and childhood …
A large review of 26 studies found that maternal infections during pregnancy are associated with an increased risk of acute lymphoblastic le…
Longitudinal TCR profiling predicts EBV, CMV, and GVHD in 108 allo-HSCT recipients
TCR Monitoring Predicts Dangerous Complications Before They Start
This longitudinal cohort study evaluated TCR beta repertoire profiling in 108 allogeneic hematopoietic stem cell transplantation recipients …
A new scan of immune cells can predict dangerous post-transplant complications weeks before symptoms appear.
From Other Specialties
SBRT plus atezolizumab shows activity in metastatic cervical cancer
Radiation plus immune therapy helps some patients with advanced cervical cancer survive longer
This prospective phase II trial evaluated SBRT followed by atezolizumab in 21 patients with metastatic, recurrent, or persistent cervical ca…
A small trial found that adding immune therapy to radiation helped some patients with advanced cervical cancer keep their disease stable for…
In-person group sessions boost fruit/vegetable intake in Latina breast cancer survivors
In-Person Sessions Boost Fruit and Vegetable Intake in Latina Breast Cancer Survivors
This randomized factorial trial in 167 Latina breast cancer survivors found that in-person group sessions increased daily fruit/vegetable in…
In-person group sessions helped Latina breast cancer survivors eat more fruits and vegetables, while the control group's intake dropped shar…
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
New drug combo did not extend life for metastatic triple-negative breast cancer patients in this trial
This phase III RCT in 812 patients with previously untreated metastatic triple-negative breast cancer found that adding capivasertib to pacl…
A large global trial found that adding capivasertib to paclitaxel did not improve overall survival for patients with metastatic triple-negat…
Contrast-enhanced mammography reduces costs per QALY in breast cancer screening recalls compared to conventional imaging
Contrast-enhanced mammography may cut costs for breast cancer screening
This RCT evaluated women recalled from breast cancer screening in a hospital setting. Contrast-enhanced mammography (CEM) as the primary too…
Using contrast-enhanced mammography as the first test for women recalled from screening could lower imaging costs without harming quality of…